SPARED合作组织:局限性前列腺癌男性部分腺体消融的患者选择
SPARED CRN是由学术与社区泌尿科医生、FDA、医疗器械流行病学网络及设备制造商组成的公私合作项目,旨在评估局限性前列腺癌部分腺体消融技术。本文报告FDA研讨会专家讨论,聚焦患者选择、手术规划、随访、研究设计及不良事件与癌症控制结局的合适对照。鉴于随机试验中患者与医生均势的挑战及部分腺体消融与全腺体治疗比较的范式转变,小组聚焦客观性能标准与目标以指导SPARED CRN中单臂研究的建立。
要点
- SPARED CRN旨在评估部分腺体消融技术安全性和有效性。
- 研讨会聚焦患者选择、手术规划、随访及研究设计框架。
- 因随机试验均势挑战,小组聚焦客观性能标准指导单臂研究。
核心结论
- 本次峰会为部分腺体消融新型医疗器械及药物/器械组合的前瞻性、多中心数据收集与评估奠定了基础。
研究设计与样本
- SPARED CRN是学术与社区泌尿科医生、FDA、医疗器械流行病学网络及设备制造商之间的公私合作项目。
- 本文报告近期FDA研讨会,专家讨论部分腺体消融的关键框架,聚焦患者选择、手术规划、随访、研究设计及不良事件与癌症控制结局的合适对照。
主要发现
- 鉴于随机试验中患者与医生均势的挑战,以及部分腺体消融与全腺体治疗比较的范式转变,小组聚焦客观性能标准与目标。
- 小组以客观性能标准与目标作为平台,指导SPARED CRN中单臂研究的建立。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The SPARED CRN (Study of Prostate Ablation Related Energy Devices Coordinated Registry Network) is a private-public partnership between academic and community urologists, the FDA (U.S. Food and Drug Administration), the Medical Device Epidemiology Network and device manufacturers to examine the safety and effectiveness of technologies for partial gland ablation in men with localized prostate cancer. MATERIALS AND METHODS: We report on a recent workshop at the FDA with thought leaders to discuss a critical framework for partial gland ablation, focusing on patient selection, surgical planning, followup, study design and appropriate comparators in terms of adverse events and cancer control outcomes. We summarize salient points from experts in urology, oncology and epidemiology that were presented and discussed in an open forum. RESULTS: Given the challenges in achieving patient and physician equipoise to perform a randomized trial, as well as an inherent paradigm shift when comparing partial gland ablation (inability to assess prostate specific antigen recurrence) to whole gland treatments, the group focused on objective performance criteria and goals as a platform to guide the creation of single arm studies in the SPARED CRN. CONCLUSIONS: This summit lays the foundation for prospective, multi-center data collection and evaluation of novel medical devices and drug/device combinations for partial gland ablation.
引用
- Gross MD, Sedrakyan A, Bianco FJ, et al. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019. PMID: 31144591. doi:10.1097/JU.0000000000000357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。